MedTrace Logo

Midodrine Use in Septic Shock

NCT03706053 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-24

Study results available
· View outcomes & findings →

Summary

The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Midodrine Hydrochloride

Midodrine Hydrochloride, enteral, 10 or 20 mg

OTHER

placebo

investigational pharmacy formulated placebo comparator

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Alexandra Kadl, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-05
Primary Completion
2022-02-11
Completion
2022-02-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706053 on ClinicalTrials.gov